GuoB, ZhengC, SuiB, et al.: A closer look to botulinum neurotoxin type A-induced analgesia. Toxicon, 2013; 71:134–139.
2.
HoareB, WallenM, ImmsC, et al.: Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE). Cochrane Database Syst Rev, 2010; CD003469.
3.
KajiR, OsakoY, SuyamaK, et al.: Botulinum toxin type A in post-stroke lower limb spasticity: A multicenter, double-blind, placebo-controlled trial. J Neurol, 2010; 257:1330–1337.
4.
LimJ, KohJ, PaikN: Intramuscular botulinum toxin-A reduces hemiplegic shoulder pain: A randomized, double-blind, comparative study versus intraarticular triamcinolone acetonide. Stroke, 2008; 39:126–131.
5.
WisselJ, GanapathyV, WardA, et al.: OnabotulinumtoxinA improves pain in patients with post-stroke spasticity: Findings from a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage, 2016; 52:17–26.
6.
MillerD, RichardsonD, EisaM, et al.: Botulinum neurotoxin-A for treatment of refractory neck pain: A randomized, double-blind study. Pain Med, 2009; 10:1012–1017.
7.
HartlD, CohenM, JuliéronM, et al.: Botulinum toxin for radiation-induced facial pain and trismus. Otolaryngol Head Neck Surg, 2008; 138:459–463.
8.
BachC, WagnerI, LachiverX, et al.: Botulinum toxin in the treatment of post-radiosurgical neck contracture in head and neck cancer: A novel approach. Eur Ann Otorhinolaryngol Head Neck Dis, 2012; 129:6–10.
9.
MittalS, MachadoD, JabbariB: OnabotulinumtoxinA for treatment of focal cancer pain after surgery and/or radiation. Pain Med, 2012; 13:1029–1033.
10.
O'DonnellC: Pectoral muscle spasms after mastectomy successfully treated with botulinum toxin injections. PM R, 2011; 3:781–782.
11.
DessyL, MarucciaM, MazzocchiM, ScuderiN: Treatment of post mastectomy pain syndrome after mastopexy with botulinum toxin. J Plast Reconstr Aesthet Surg, 2014; 67:873–874.
12.
FabregatG, Asensio-SamperJ, PalmisaniS, et al.: Subcutaneous botulinum toxin for chronic post-thoracotomy pain. Pain Pract, 2013; 13:231–234.
13.
WuC, LianY, ZhengY, et al.: Botulinum toxin type A for the treatment of trigeminal neuralgia: Results from a randomized, double-blind, placebo-controlled trial. Cephalalgia, 2012; 32:443–450.
14.
XiaoL, MackeyS, HuiH, et al.: Subcutaneous injection of botulinum toxin A is beneficial in postherpetic neuralgia. Pain Med, 2010; 11:1827–1833.
15.
ApallaZ, SotiriouE, LallasA, et al.: Botulinum toxin A in postherpetic neuralgia: A parallel, randomized, double-blind, single-dose, placebo-controlled trial. Clin J Pain, 2013; 29:857–864.
16.
OndoW, HunterC, MooreW: A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology, 2004; 62:37–40.
17.
JacksonC, GronsethG, RosenfeldJ, et al.: Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve, 2009; 39:137–143.
18.
YoungC, EllisC, JohnsonJ, et al.: Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis. Cochrane Database Syst Rev, 2011; CD006981.
19.
WollmerM, de BoerC, KalakN, et al.: Facing depression with botulinum toxin: A randomized controlled trial. J Psychiatr Res, 2012; 46:574–581.
20.
FinziE, RosenthalE: Treatment of depression with onabotulinumtoxinA: A randomized, double-blind, placebo controlled trial. J Psychiatr Res, 2014; 52:1–6.
21.
MagidM, ReichenbergJ, PothP, et al.: Treatment of major depressive disorder using botulinum toxin A: A 24-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry, 2014; 75:837–844.
22.
CavalliniM, CirilloP, FundaròS, et al.: Safety of botulinum toxin A in aesthetic treatments: A systematic review of clinical studies. Dermatol Surg, 2014; 40:525–536.
23.
KeuhnB: FDA Requires black box warnings on labeling for botulinum toxin products. JAMA, 2009; 301:2316.
24.
NaumannM, JankovicJ: Safety of botulinum toxin type A: A systematic review and meta-analysis. Curr Med Res Opin, 2004; 20:981–990.
